000099343 001__ 99343
000099343 005__ 20221004075858.0
000099343 0247_ $$2doi$$a10.2147/JPR.S203903
000099343 0248_ $$2sideral$$a122902
000099343 037__ $$aART-2019-122902
000099343 041__ $$aeng
000099343 100__ $$aCamps Herrero, C.
000099343 245__ $$aWorking towards a consensus on the oncological approach of breakthrough pain: A Delphi survey of Spanish experts
000099343 260__ $$c2019
000099343 5060_ $$aAccess copy available to the general public$$fUnrestricted
000099343 5203_ $$aPurpose: There is a lack of standards for the diagnosis, assessment and management of breakthrough cancer pain (BTcP). La Fundación ECO (the Foundation for Excellence and Quality in Oncology) commissioned a study to establish a consensus and lay the foundations for the appropriate management of BTcP in oncology patients.
Patients and methods: A modified Delphi survey comprising two rounds was used to gather and analyze data, which was conducted over the Internet. Each statement that reached a consensus with the respondents was defined as a median consensus score (MED) of =7, and agreement among panelists as an interquartile range (IQR) of =3.
Results: In total, 69 medical oncologists responded, with a broad consensus that BTcP implied exacerbations of high-intensity pain, as opposed to moderate pain. Furthermore, they concurred that appropriate diagnostic equipment is needed, and that rapid-onset fentanyl formulations should be the preferred treatment for BTcP management. The panelists agreed that a lack of appropriate information and training to attend to patients, as well as limited patient visitation rights, were barriers to effective BTcP management. Regarding gaps in detected knowledge, the panelists were unsure of the measures necessary to assess the burden of the disease on the patient’s quality of life and associated medication costs. Alongside this, there was a lack of awareness of the technical specifics of the different formulations of rapid-onset fentanyl.
Conclusion: These results represent the current status of BTcP management. They may inform recommendations and provide a framework for future research.
000099343 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000099343 590__ $$a2.386$$b2019
000099343 591__ $$aCLINICAL NEUROLOGY$$b119 / 204 = 0.583$$c2019$$dQ3$$eT2
000099343 592__ $$a0.788$$b2019
000099343 593__ $$aAnesthesiology and Pain Medicine$$c2019$$dQ1
000099343 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000099343 700__ $$0(orcid)0000-0002-9159-4988$$aAnton Torres, A.$$uUniversidad de Zaragoza
000099343 700__ $$aCruz-Hernández, J.J.
000099343 700__ $$aCarrato, A.
000099343 700__ $$aConstenla, M.
000099343 700__ $$aDíaz-Rubio, E.
000099343 700__ $$aFeyjoo Saus, M..
000099343 700__ $$aGarcia-Foncillas, J.
000099343 700__ $$aGascón, P.
000099343 700__ $$aGuillem, V.
000099343 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000099343 773__ $$g12 (2019), 2349-2358$$pJ. pain res.$$tJournal of Pain Research$$x1178-7090
000099343 8564_ $$s215166$$uhttps://zaguan.unizar.es/record/99343/files/texto_completo.pdf$$yVersión publicada
000099343 8564_ $$s2660823$$uhttps://zaguan.unizar.es/record/99343/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000099343 909CO $$ooai:zaguan.unizar.es:99343$$particulos$$pdriver
000099343 951__ $$a2022-10-03-14:34:48
000099343 980__ $$aARTICLE